S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Atossa Therapeutics Stock Price, News & Analysis (NASDAQ:ATOS)

$0.75
+0.02 (+2.73%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.72
$0.77
50-Day Range
$0.63
$0.81
52-Week Range
$0.50
$1.39
Volume
191,714 shs
Average Volume
274,561 shs
Market Capitalization
$94.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Atossa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
563.8% Upside
$5.00 Price Target
Short Interest
Bearish
5.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Atossa Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.24) to ($0.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

725th out of 932 stocks

Pharmaceutical Preparations Industry

344th out of 431 stocks


ATOS stock logo

About Atossa Therapeutics Stock (NASDAQ:ATOS)

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Stock Price History

ATOS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Q2 2023 Atossa Therapeutics Inc Earnings Call
See More Headlines
Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATOS
Employees
11
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+563.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.93 per share

Miscellaneous

Free Float
115,530,000
Market Cap
$94.38 million
Optionable
Not Optionable
Beta
1.21

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Steven C. Quay FCAP (Age 72)
    M.D., Ph.D., Chairman, CEO & President
    Comp: $1.14M
  • Ms. Heather Rees (Age 51)
    SVP, Finance & Principal Accounting Officer
  • Ms. Delly Behen P.H.R.
    Vice President of Administration & Human Resources
  • Mr. Eric Van Zanten
    Vice President of Investor & Public Relations
  • Dr. Richard Graydon M.D.
    Ph.D., Interim Chief Medical Officer














ATOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings
or view top-rated stocks.

What is Atossa Therapeutics' stock price target for 2024?

1 brokerages have issued 1 year price objectives for Atossa Therapeutics' stock. Their ATOS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 563.8% from the stock's current price.
View analysts price targets for ATOS
or view top-rated stocks among Wall Street analysts.

How have ATOS shares performed in 2023?

Atossa Therapeutics' stock was trading at $0.5285 at the start of the year. Since then, ATOS shares have increased by 42.5% and is now trading at $0.7532.
View the best growth stocks for 2023 here
.

When is Atossa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ATOS earnings forecast
.

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

When did Atossa Therapeutics' stock split?

Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).

Who are Atossa Therapeutics' major shareholders?

Atossa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.11%), UBS Group AG (0.03%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATOS) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -